

# miR-596 suppresses the expression of Survivin and enhances the sensitivity of osteosarcoma cells to the molecular targeting agent anlotinib

This article was published in the following Dove Press journal:  
*OncoTargets and Therapy*

Leisheng Wang<sup>1,\*</sup>  
He En<sup>2,\*</sup>  
Lei Yang<sup>3</sup>  
Yanbing Zhang<sup>2</sup>  
Baisheng Sun<sup>4</sup>  
Jianjiang Gao<sup>5</sup>

<sup>1</sup>Department of Orthopedics, Yantaishan Hospital, Yantai, Shandong Province 264000, People's Republic of China;

<sup>2</sup>Department of Outpatient, The 81st Group Army Hospital of Chinese People's Liberation Army, Zhangjiakou City, Hebei Province, People's Republic of China; <sup>3</sup>Department of Outpatient, The 80th Group Army Hospital of Chinese People's Liberation Army (formerly the 89th Hospital of the People's Liberation Army), Weifang City, Shandong Province, People's Republic of China; <sup>4</sup>Department of Emergency, The Fifth Medical Center of the General Hospital of the Chinese People's Liberation Army (formerly the 307th Hospital of the People's Liberation Army), Beijing 100071, People's Republic of China; <sup>5</sup>Department of Emergency, Haiyang People's Hospital, Haiyang, Shandong 265100, People's Republic of China

\*These authors contributed equally to this work

Correspondence: Jianjiang Gao  
Department of Emergency, Haiyang People's Hospital, No. 73 Haiyang Road, Haiyang, Shandong Province 265100, People's Republic of China  
Tel +86 535 322 6638  
Fax +86 535 322 6815  
Email [jianjiang\\_gao@sohu.com](mailto:jianjiang_gao@sohu.com)

**Background:** Osteosarcoma (OSA), the most common primary bone malignancy, is characterized by a wide spectrum of complicated pathologies and frequent distal metastasis and causes death in adolescents and young adults worldwide. Antitumor drug treatment strategies include various cytotoxic chemotherapy drugs, while molecular targeted therapy for OSA is currently less used. The present work revealed the role played by the miR-596/Survivin axis in affecting the sensitivity of OSA cells to anlotinib, a novel molecular targeting agent.

**Methods:** By virtual screening, we found that miR-596 might target Survivin by using an online tool (miRDB). RNA levels of miR-596 and Survivin in clinical specimens were examined with qPCR. The effect of miR-596 on anlotinib's antitumor effect was examined with MTT experiments, the subcutaneous tumor model, or the intramuscular tumor model.

**Results:** Overexpression of miR-596 via lentiviral particles repressed the protein level of Survivin in U2OS cells. Transfection of miR-596 enhanced the antitumor effect of anlotinib on U2OS cells or five cell lines derived from OSA patients.

**Conclusion:** miR-596 targets Survivin and enhances the antitumor effect of anlotinib on OSA cells.

**Keywords:** osteosarcoma cell, microRNAs, Survivin, molecular targeting agents, anlotinib

## Introduction

Osteosarcoma (OSA), which is considered as the most common bone malignancy, is characterized by complicated pathologies and sometimes distal metastasis.<sup>1,2</sup> Patients suffering from localized/primary OSA often have a good (about 60–80%) 5-year survival rate, whereas the 5-year survival rate is decreased to about 15–30% in patients with metastatic or recurrent OSA.<sup>3,4</sup> Consequently, chemotherapeutic treatments combined with surgical resection have been widely used to treat OSA, while molecular-targeted therapy for OSA is currently less used. Although the biology and genetics of OSA have gained attention, the clinical outcomes of OSA patients have not yet significantly improved.<sup>3</sup> It has been reported that the occurrence and progress of malignant/metastatic OSA are often driven by genetic or pathological alterations.<sup>5</sup> Increasing evidences have confirmed that the inhibition of angiogenesis process could decelerate the progress or metastasis of OSA.<sup>5</sup> Therefore, angiogenesis inhibitors could be used to treat advanced OSA.<sup>5</sup>

Anlotinib is an orally available, highly potent multitargeting protein-kinase inhibitor that could block the activation of some receptor tyrosine protein kinase

(RTKs), eg, VEGFR2 (vascular endothelial growth factor receptor 2), platelet-derived growth factor receptors  $\alpha/\beta$  (PDGFR  $\alpha/\beta$ ), Ret, c-Kit, c-FMS, or discoidin domain receptor 1 (DDR1).<sup>6,7</sup> It has been reported that anlotinib revealed an antitumor effect when used in clinical trials in a variety of human solid tumors, for example non-small-cell lung cancer (NSCLC), hepatocarcinoma (HCC), gastric cancer, renal carcinoma (RC), or soft tissue sarcoma.<sup>8–10</sup> In 2018, anlotinib was approved by the China Food and Drug Administration (CFDA) for the clinical application of NSCLC treatment.<sup>8–10</sup> Therefore, demonstrating the therapeutic effects of anlotinib on OSA cells not only helps to deepen our understanding of anlotinib but also provides more options for the diagnosis and treatment of OSA.

Survivin is a key regulator of cellular survival and injury response. In malignant human cells, Survivin enhances cell survival and decreases apoptosis in response to cellular injury, eg, ion radiation or antitumor agents.<sup>11–13</sup> It has been reported that Survivin could be involved in antitumor agents' resistance.<sup>14</sup> Thus, targeting Survivin is a potential approach to more effective antitumor treatment. MicroRNAs (miRNAs), which have emerged as post-transcriptional modulators of target genes, are endogenous small noncoding RNAs that have been found to have critical roles in functioning as tumor suppressors.<sup>15–18</sup> In the current study, we demonstrated that Survivin was correlated with the prognosis of overall survival (OS) or progression-free survival (PFS) of OSA patients. We also demonstrated that miR-596 enhanced the antitumor effect of anlotinib by targeting Survivin. Therefore, targeting Survivin by miR-596 is a promising approach to achieve effective molecular targeting therapies in OSA treatment.

## Materials and methods

### Patients and specimens

The collection of clinical specimens and protocols of this work were approved by the Ethics Committee of Yantaishan Hospital. The collection and usage of clinical specimens were with written informed consent from patients, and all protocols or experiments were conducted in accordance with the Declaration of Helsinki. Total RNA samples, extracted from a cohort including 74 tumor and adjacent nontumor tissues and evaluated by accepted pathological and radiological criteria, were conserved in our laboratory and used in this study. The baseline information of the cohort was shown as [Table S1](#). The

prognoses of patients were determined as OS or PFS. The data of TCGA database were also searched following the methods provided by Cao et al (2019) and Fan et al (2019).<sup>19,20</sup>

### Cell lines and reagents

U2OS, a typical OSA cell line, was purchased from the cell resources center of the Chinese Academy of Medical Sciences (Beijing, China). Five patient-derived cell lines (PDCs) were separated from the clinical specimens obtained from five patients with OSA during surgery as part of normal medical care. The lentivirus particles of pri-miR-596 or Survivin with a mutation of miR-596 targeted sequences located in 3'-UTR were constructed and purchased (Vigene Corporation, Jinan City, Shandong Province, China). The wild-type sequence or sequence with mutated miR-596-binding site of Survivin's 3'UTR (1921–2100) was obtained by chemical synthesis and cloned into pGL4.26 plasmids to construct luciferase reporters by Vigene Corporation. The luciferase containing wild-type sequence of Survivin's 3'UTR with miR-596-binding site was named as Luc, whereas the luciferase containing sequence of Survivin's 3'UTR with mutated miR-596-binding site was named as Luc<sup>Mut</sup>. The inhibitor of the miR-596 was purchased from Thermo Fisher Scientific (Waltham, MA, USA). The antitumor agents doxorubicin (Selleck, TX, USA), cisplatin (Selleck), methotrexate (Selleck), or anlotinib (Selleck) were dissolved in DMSO and conserved in an  $-80^{\circ}\text{C}$  condition.

### Quantitative polymerase chain reaction

Total RNA samples were extracted from clinical specimens, and qPCR experiments were performed, following protocols provided by the manufacturer (Applied Biosystems, Thermo Fisher Scientific, ) and methods described by Ji et al (2017) and Liang et al (2017).<sup>3,15</sup> The expression of Survivin was examined by qPCR with the following primers: Survivin (birc5), forward sequence, 5'-CCACTGAG AACGAGCCA GACTT-3'; reverse sequence 5'-GTATTA CAGGCGTAAGCCACCG-3'; loading control (gapdh), forward sequence, 5'-GTCTCCTCTGACTTCAACAGCG-3'; reverse sequence, 5'-ACCACCCTGTTGCTGTAGCCA A-3'.

### Luciferase experiments

Cells were transfected with control miRNA + Luc, miR-596 + Luc, miR-596 + inhibitor + Luc or miR-596 + LucMut. Then, cells were harvested for luciferase experiments.

Luciferase experiments were performed by using a luciferase examination kit (Promega Corporation, Madison, WI, USA) following the instructions provided by the manufacturer and methods described by Ma et al (2016) and Wang et al (2019).<sup>21,22</sup> The relative luciferase activation was calculated as: [(luciferase activation of control group/ $\beta$ -galactosidase activation of control group)/(luciferase activation of administration group/ $\beta$ -galactosidase administration of control group)]  $\times$  100%. Results were shown as mean  $\pm$  SD of relative luciferase activation.

## Cell culture and survival examination

Cells were cultured in DMEM medium (Invitrogen, Carlsbad, CA, USA), with the addition of 10% FBS at 37°C with a 5% CO<sub>2</sub> condition. Cells were seeded into a 96-well plate (Corning, Inc.) and incubated with the indicated concentrations of antitumor agents diluted by sorafenib DMSO solution (Table S1). After 48 hrs of treatment, cells were harvested for MTT experiments, following the methods described by Feng et al (2018).<sup>23</sup> The inhibition rates of antitumor agents on cells were calculated, following the methods provided by Feng et al (2018).<sup>19</sup> The half-maximal inhibitory concentration values (IC<sub>50</sub> values) were calculated based on inhibition rates, following the methods described by Guan et al (2017) and Li et al (2018).<sup>24,25</sup>

## Antibodies and Western blot

Antibodies to Survivin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were obtained from Abcam (Cambridge, UK). OSA cells transfected with control, miR-596, miR-596 + Survivin<sup>Mut</sup>, or miR-596 + inhibitor were harvested 48 hrs following transfection, and total protein samples were extracted for Western blot experiments. Western blots were performed following a standard method. In brief, total protein samples extracted from OSA cells were separated using SDS-PAGE. Following electrophoresis, protein samples in SDS-PAGE gels were transferred onto polyvinylidene fluoride (PVDF) membranes and blocked, using 5% BSA diluted in tris-buffered saline with Tween 20 (TBST buffer). Membranes were subsequently incubated with the relevant primary and secondary antibodies before detection by chemiluminescence.

## Animal experiments

The Ethics Committee of Yantai Hospital approved the methods of animal experiments in this study. All animal

experiments were carried out in accordance with the UK Animals (Scientific Procedures) Act of 1986 and its associated guidelines.<sup>26,27</sup> Cells (U2OS or PDC) were used to form PDX (patient-derived tumor xenograft) and were cultured ( $2 \times 10^7$  cells per inoculation point) and seeded into the subcutaneous position of nude mice (T-cell deficiency mice) aged 4–6 weeks to form subcutaneous tumor tissues. After 5–6 days, the mice received antitumor agents (anlotinib) once per 2 days. After 4–5 weeks of treatment, the mice were harvested, and subcutaneous tumors were collected.

Tumor weights were measured by the precision balance. Tumor volumes were measured by tumor width  $\times$  tumor width  $\times$  tumor length/2.<sup>28,29</sup> The inhibition rates of anlotinib on OSA cells were calculated based on tumor volumes or tumor weights. The formulas used to calculate inhibition rates are as follows: 1) (control group's tumor volumes – anlotinib group's tumor volume)/(control group's tumor volumes) and 2) (control group's tumor weight – anlotinib group's tumor weight)/(control group's tumor volumes). The IC<sub>50</sub> values of anlotinib on OSA cells' subcutaneous growth were calculated based on the inhibition rates.

Next, cells were mixed with biological-medical gel (Cai-Hong-Yi-Xue-She-Bei, Kunming, China) and injected into muscle tissue located in the legs of nude mice ( $5 \times 10^5$  cells per site). After 4–6 weeks' growth, mice were injected with F-FDG,<sup>18</sup> received MicroPET, and were examined following the methods described by Xu et al (2013).<sup>30</sup> Next, the mice were harvested, and the muscle tissue was collected for H&E staining.<sup>31</sup> Images of the results from MicroPET or H&E staining were quantitatively analyzed via Image J software, according to previously detailed methods.<sup>32,33</sup> The inhibition rate of each group was calculated following the methods provided by Wei et al (2019).<sup>34</sup>

## Statistical analysis

Statistical analysis was performed by Bonferroni's correction with or without two-way ANOVA methods using SPSS (Version No. 8.0; IBM Corporation, Armonk, NY, USA). The IC<sub>50</sub> values of anlotinib on OSA cells were calculated by Origin Software, version 8.5 (OriginLab, Northampton, MA, USA). A *P*-value of <0.05 was considered statistically significant between the results from two groups.


## Results

### The expression of miR-596/Survivin and correlations with clinical parameters in OSA patients

Survivin was a potential target of miR-596; the italicized font in Figure 1A indicates the potential targeted sequence within PXR mRNA's 3'-UTR (Figure 1). Next, U2OS cells infected with control, miR-596, miR-596 + Survivin<sup>Mut</sup>, or miR-596 + inhibitor were harvested for Western blot 48 hrs after transfection. Results showed that compared to the control group, miR-596 significantly decreased the expression of Survivin (Figure 1B and C) but not Survivin<sup>Mut</sup>, which contains a mutated sequence


of the miR-596-binding site (Figure 1A–C). Moreover, transfection of miR-596's inhibitor almost blocked the effect of miR-596 on Survivin's expression. To further examine the specificity of miR-596 on Survivin's expression, luciferase reporters were used. As shown in Supplemental Figure 1, miR-596 inhibited the activation of luciferase reporters containing 3'UTR sequences, including the miR-596-targeting site. Transcription of the miR-596 inhibitor or mutated vectors blocked the effect of miR-596 on luciferase reporters' activation (Figure S1).

Next, the expression of Survivin or miR-596 in clinical specimens was examined. As shown in Figure 2A and B, the expression of Survivin is much higher in OSA



**Figure 1** miR-596 targets Survivin's 3'-UTR. (A) The bold, italicized type image indicates the potential miR-596-binding sites or mutated sites located in Survivin's 3'-UTR. (B) U2OS cells, which were transfected with control (control miRNA), miR-596, miR-596 + Survivin<sup>Mut</sup>, or miR-596c + its inhibitor, were harvested for Western blot experiments. The protein level of Survivin or GAPDH in U2OS cells was examined by their antibodies, and GAPDH was chosen as the loading control. Results were shown as images from Western blot (B) or quantitative analysis results (C). \* $P < 0.05$ .

**Abbreviations:** miR, microRNA; Mut, mutation.



**Figure 2** Expression of Survivin and miR-596 in clinical specimens. RNA levels of Survivin (A) or miR-596 were examined in 74 paired nontumor/tumor clinical tissues. \* $P < 0.05$  versus nontumor group with tumor group.


**Abbreviation:** miR, microRNA.

specimens than in paired nontumor specimens, whereas the expression of miR-596 is much lower in OSA specimens than in paired nontumor specimens. To further investigate the clinical significance of miR-596/Survivin, the relationship between Survivin or miR-596 levels and prognoses of patients was examined. As shown in Figure 3 and Tables 1 and 2, Kaplan–Meier survival analysis indicated that patients with high levels of Survivin had a poorer OS and PFS than those with low Survivin levels, whereas patients with high levels of miR-596 showed better OS and PFS than those with low miR-596 levels. Moreover, results shown in Figure 4 further confirm that the expression of Survivin is negatively correlated with miR-596 in

OSA specimens. Therefore, miR-596 could repress the expression of Survivin by targeting Survivin mRNA's 3'-UTR directly.

### miR-596 enhances the sensitivity of OSA cells to anlotinib

MTT assays were performed to determine whether miR-596 enhances the in vitro antitumor effect of anlotinib on OSA cells. As shown in Figure 5 and Table 3, anlotinib inhibited the survival of U2OS cells. Transfection of miR-596 enhanced the sensitivity of OSA cells to anlotinib, and the IC<sub>50</sub> values of anlotinib were, respectively, decreased (Table 3). The effects of anlotinib treatment on



**Figure 3** Expression of Survivin/miR-596 and correlation with patients' prognosis (A–B). Kaplan–Meier survival curves and log-rank tests were used to compare the OS (A) or PFS (B) of low-Survivin group and high-Survivin group patients (C–D). Kaplan–Meier survival curves and log-rank tests were used to compare the OS (C) or PFS (D) of low-miR-596 group and high-miR-596 group patients. (E) The representative image of clinical specimens by qPCR and DNA electrophoresis. \* $P < 0.05$ .

**Abbreviations:** miR, microRNA; OS, overall survival; PFS, progression-free survival.

**Table 1** miR-596 expression and clinical outcome of osteosarcoma patients


	miR-596 mRNA expression		P
	High (n=37)	Low (n=37)	
PFS	66.8 56.8–76.8 (M)	50.3 41.2–59.4 (M)	0.041
OS	70.2 60.2–80.2 (M)	52.7 42.8–62.0 (M)	0.036

**Abbreviations:** PFS, progress free survival; OS, overall survival; M, months.

**Table 2** Survivin expression and clinical outcome of osteosarcoma patients

	Survivin mRNA expression		P
	High (n=37)	Low (n=37)	
PFS	50.5 41.2–59.7 (M)	65.3 56.0–74.6 (M)	0.035
OS	51.1 41.2–61.0 (M)	70.3 60.7–79.9 (M)	0.022

**Abbreviations:** PFS, progress free survival; OS, overall survival; M, months.




**Figure 4** Correlation of RNA levels of miR-596 and Survivin in clinical tumor specimens from osteosarcoma patients. The relationship between the RNA levels of miR-596 and Survivin was assessed by Spearman's rank correlation analysis. The symbols represent individual samples (a total of 74 specimens).

**Abbreviation:** miR, microRNA.

OSA cell lines from the five patients (PDCs) are also shown in Table 3. Anlotinib inhibited the survival of the OSA cells (PDCs) in a dose-dependent manner, and the IC<sub>50</sub> values of anlotinib on PDCs' survival were, respectively, decreased.

Next, the effect of miR-596 and anlotinib coadministration on OSA cells was examined in a subcutaneous model. As shown in Figure 6 and Table 4, anlotinib inhibited the subcutaneous growth of U2OS cells in nude mice.



**Figure 5** miR-596 enhances the antitumor effect of anlotinib on cultured U2OS cells. U2OS cells transfected with control miRNA or miR-596 were treated with the indicated concentration of anlotinib. Cells were harvested for MTT experiments, and the inhibition rates of anlotinib were calculated by OD490 nm. \*P<0.05. **Abbreviation:** miR, microRNA.

Transfection of miR-596 enhanced the antitumor effect of anlotinib on OSA cells' subcutaneous growth, and the IC<sub>50</sub> values of anlotinib on OSA cells' subcutaneous growth were, respectively, decreased. The effect of anlotinib treatment on the PDX model, formed by PDC cell lines from the five patients, is shown in Table 4. Anlotinib inhibited the survival of PDC cells in a dose-dependent manner. To further examine the antitumor effect of anlotinib on OSA cells, U2OS cells were injected into the muscle tissues of nude mice. As shown in Figures 7 and 8, U2OS cells can form tumor lesions in the muscle tissues of nude mice. Anlotinib inhibited the growth of U2OS cells in nude mice muscle tissues, and miR-596 enhanced the antitumor effects of anlotinib on U2OS cells.

Moreover, the specificity of miR-596 on anlotinib-inhibiting OSA cell survival or growth was examined. As shown in Figures 7–9, and Table 1, Survivin<sup>Mut</sup>-expressed cells and tumors could not be affected by miR-596. Therefore, miR-596 enhances the sensitivity of OSA cells to anlotinib.


## miR-596 enhances the sensitivity of OSA cells to cytotoxic chemotherapies

To further determine whether miR-596 enhances the in vitro antitumor effect of other antitumor agents, MTT assays were performed. As shown below, the cytotoxic chemotherapies doxorubicin (Table 5), cisplatin (Table 6), or methotrexate (Table 7) inhibited the survival of U2OS cells in a dose-dependent manner. Transfection of miR-596 enhanced the sensitivity of OSA to other antitumor agents, and the IC<sub>50</sub> values of anlotinib were, respectively, decreased. Therefore, miR-596 enhances the sensitivity of OSA cells to cytotoxic chemotherapies. The

**Table 3** The IC<sub>50</sub> values of anlotinib on osteosarcoma cell lines

Cell lines	Control	miR-596	miR-596 + Survivin <sup>Mut</sup>	miR-596 + inhibitor
	IC <sub>50</sub> values (μmol/L) of anlotinib			
U2OS	0.66±0.11	0.21±0.02	0.58±0.15	0.49±0.08
PDC-1	0.75±0.22	0.15±0.01	0.70±0.20	0.55±0.10
PDC-2	0.80±0.25	0.28±0.05	0.78±0.23	0.65±0.13
PDC-3	0.65±0.30	0.10±0.03	0.67±0.33	0.56±0.15
PDC-4	0.71±0.33	0.20±0.04	0.53±0.25	0.60±0.07
PDC-5	0.75±0.10	0.35±0.02	0.72±0.24	0.63±0.14

**Abbreviation:** PDC, patient-derived cells.



**Figure 6** miR-596 enhances the antitumor effect of anlotinib on U2OS cell subcutaneous growth. U2OS cells transfected with control or miR-596 were injected into nude mice to form subcutaneous tumors. Four days to 5 days after injection, mice received orally administrated concentrations of anlotinib once per 2 days. After 10 treatments (about 3 weeks), mice were harvested, and tumor tissues were harvested. Results are shown as images of subcutaneous tumors (A), tumor volumes (B), tumor weights (C), inhibition rates of anlotinib calculated by tumor volumes (D), or inhibition rates of anlotinib calculated by tumor weights (E). \*P<0.05.

**Abbreviations:** miR, microRNA; Mut, mutation; Anl, anlotinib.

**Table 4** The IC<sub>50</sub> values of anlotinib on osteosarcoma cell lines in nude mice

Cell lines	Control	miR-596
	IC <sub>50</sub> values (mg/kg) of anlotinib	
U2OS	2.50±0.75	0.33±0.11
PDX-1	2.88±0.55	0.50±0.05
PDX-2	1.97±0.30	0.44±0.10
PDX-3	2.32±0.51	0.76±0.22
PDX-4	1.62±0.29	0.35±0.10
PDX-5	1.98±0.46	0.55±0.25


**Abbreviation:** PDX, patient-derived tumor xenograft.

effects of anlotinib treatment on the OSA cell lines from the five patients are shown in Table 2. Anlotinib inhibited the survival of OSA cells in a dose-dependent manner, and

miR-596 enhanced the antitumor effect of anlotinib on OSA cells.

## Discussion

Currently, one of the main strategies for molecular targeted therapy of malignant tumors is the oral administration of small-molecule multitarget protein kinase inhibitors.<sup>35,36</sup> These drugs can directly inhibit the RTK and mitogen-activated protein kinase as well as other signaling pathways to inhibit malignant tumors delaying cell proliferation or decelerating tumor tissue growth. Molecular targeting agents also can inhibit tumor cell metastasis, invasion, and tumor angiogenesis by inhibiting RTK, such as in VEGFR.<sup>37-41</sup> Anlotinib is a new molecular targeted drug with intellectual property rights in China and has strong inhibitory effects on VEGFR and




**Figure 7** miR-596 enhanced the antitumor activation of anlotinib on U2OS cell subcutaneous growth by targeting Survivin. U2OS cells transfected with control miRNA, miR-596, or miR-596 + Survivin<sup>Mut</sup> were seeded into nude mice to form subcutaneous tumors. The mice received a 0.5 mg/kg dose of anlotinib (a dose without significant antitumor effect) by oral administration. The results are shown as **(A)** images of subcutaneous tumors, **(B)** tumor volumes, and **(C)** or tumor weight **(D)** tumor weights. The inhibition rate calculated by tumor volume **(E)** is shown. \* $P < 0.05$ .

**Abbreviation:** miR, microRNA.

c-Kit.<sup>8–10</sup> However, these molecularly targeted drugs also face many challenges in clinical use: molecular targeted drugs are expensive and drug resistant.<sup>42</sup> At the same time, the toxic side effects of these drugs cannot be ignored.<sup>43</sup> Therefore, how to achieve more safe and effective molecular targeted therapy and to achieve lower doses of drugs that achieve antitumor effect is an urgent problem to be solved. The results of this study

indicate that the use of miR-596 can significantly increase the killing effect of anlotinib on OSA cells, using a lower dose to achieve an equal, or even greater, antitumor effect. This study uses not only existing cell lines but also patient-derived tumor cells, which helps to increase our understanding of anlotinib and also provides an experimental basis for establishing safer, more effective molecular-targeted therapy.






**Figure 8** miR-596 enhances the antitumor effect of anlotinib on U2OS cell growth in muscle tissues of mice via <sup>micro</sup>PET screening. U2OS cells transfected with control, miR-596, or miR-596 + Survivin<sup>Mat</sup> were injected into muscle tissues to form tumor lesions. Four days to 5 days after intramuscular injection of U2OS cells, mice received oral administration of a 1mg/kg dose of anlotinib once per 2 days. After 10 treatments with anlotinib, mice received <sup>micro</sup>PET screening. Results were shown as <sup>micro</sup>PET images: (A) intensity of <sup>18</sup>F-FDG of <sup>micro</sup>PET images and (B) radioactivation of tumor tissues to blood. (C) The radio-activation of tumor tissues to blood was shown as quantitative results. \*P<0.05.

**Abbreviations:** miR, microRNA; PET, positron emission computed tomography; <sup>18</sup>F-FDG, <sup>18</sup>F-Fludeoxyglucose.

Survivin, also called baculoviral inhibitor of apoptosis repeat-containing (BIRC5), API4, EPR-1, or baculoviral IAP repeat-containing 5, is a protein that, in humans, is encoded by the BIRC5 gene.<sup>44-46</sup> Survivin is currently found to be the most potent cell survival antiapoptotic regulator.<sup>47,48</sup> Antitumor drugs used in molecular targeted therapy can damage and kill tumor cells, or damage and cause death due to injury factors.<sup>49,50</sup> Survivin can act as a major regulator of the tumor cell damage response and can play a protective role for cells.<sup>51,52</sup> This study found that the expression of Survivin in adjacent tissues was significantly lower than that in cancer tissues, while the trend of miR-596 was

exactly the opposite. At the same time, the use of miR-596 to downregulate the expression of Survivin can upregulate the sensitivity of OSA cells to anlotinib. The use of miR-596 to downregulate the expression of Survivin also upregulates the sensitivity of OSA cells to some cytotoxic chemotherapeutic drugs. Moreover, the BCL-xL, BAX, Casp 9, Casp 3, and p21 are the negative regulators of cancer cell proliferation or cell cycle. It is valuable to examine the expression of these factors and develop the therapeutic strategies based on these factors.<sup>53</sup> Some other pathways, such as Notch pathway, can function as regulating hub that modulates the expression of Survivin, CL-xL, BAX, Casp 9, Casp 3, and p21.<sup>54-57</sup>



**Figure 9** miR-596 enhances the antitumor effect of anlotinib on U2OS cell growth in muscle tissues. U2OS cells transfected with control, miR-596, or miR-596 + Survivin<sup>Mut</sup> were injected into muscle tissues to form tumor lesions. Four days to 5 days after intramuscular injection of U2OS cells, mice received oral administration of 1mg/kg dose of anlotinib once per 2 days. After 10 treatments, mice were harvested, and muscle tissues were harvested for H&E staining. Results were shown as (A) images from H&E staining and (B) inhibition rates of anlotinib on intramuscular growth of U2OS cells. \*P<0.05.

**Abbreviation:** miR, microRNA.

**Table 5** The IC<sub>50</sub> values of Doxorubicin on osteosarcoma cell lines

Cell lines	Control	miR-596	miR-596 + Survivin <sup>Mut</sup>	miR-596 + inhibitor
	IC <sub>50</sub> values (μmol/L) of doxorubicin			
U2OS	0.25±0.04	0.05±0.01	0.19±0.01	0.22±0.04
PDC-1	0.40±0.10	0.06±0.02	0.30±0.05	0.25±0.03
PDC-2	0.35±0.06	0.10±0.02	0.33±0.10	0.26±0.05
PDC-3	0.41±0.12	0.21±0.05	0.36±0.08	0.35±0.02
PDC-4	0.50±0.03	0.08±0.01	0.48±0.05	0.40±0.03
PDC-5	0.15±0.00	0.01±0.00	0.10±0.01	0.12±0.01

**Abbreviation:** PDCs, patient-derived cells.

**Table 6** The IC<sub>50</sub> values of cisplatin on osteosarcoma cell lines

Cell lines	Control	miR-596	miR-596 + Survivin <sup>Mut</sup>	miR-596 + inhibitor
	IC <sub>50</sub> values (μmol/L) of cisplatin			
U2OS	0.44±0.14	0.11±0.03	0.35±0.04	0.29±0.01
PDC-1	0.60±0.09	0.15±0.01	0.50±0.10	0.46±0.16
PDC-2	0.46±0.04	0.10±0.02	0.43±0.05	0.36±0.04
PDC-3	0.38±0.10	0.10±0.03	0.35±0.07	0.56±0.15
PDC-4	0.59±0.09	0.20±0.04	0.53±0.25	0.60±0.07
PDC-5	0.36±0.04	0.35±0.02	0.33±0.24	0.28±0.07

**Abbreviation:** PDCs, patient-derived cells.

**Table 7** The IC<sub>50</sub> values of methotrexate on osteosarcoma cell lines

Cell lines	Control	miR-596	miR-596 + SurvivinMut	miR-596 + inhibitor
	IC <sub>50</sub> values (μmol/L) methotrexate			
U2OS	0.58±0.11	0.12±0.03	0.54±0.06	0.51±0.15
PDC-1	0.45±0.06	0.09±0.02	0.35±0.13	0.40±0.04
PDC-2	0.32±0.22	0.07±0.01	0.25±0.10	0.30±0.06
PDC-3	0.31±0.02	0.16±0.05	0.40±0.20	0.56±0.15
PDC-4	0.45±0.09	0.25±0.04	0.53±0.25	0.35±0.16
PDC-5	0.32±0.08	0.08±0.01	0.25±0.06	0.22±0.05

**Abbreviation:** PDCs, patient-derived cells.

Therefore, it is valuable to examine the effect of Notch pathway on anlotinib.

Overexpression of miRNA via virus vectors has been considered as a promising approach to inhibit the proliferation or metastasis of cancer cells.<sup>58–64</sup> In the present work, miR-596 was identified in clinical specimens and was prepared as lentivirus particles. Besides miR-596, microRNA-330-5p, microRNA-218, miR-542-3p, or miR-494 could also target Survivin and inhibit the proliferation or metastasis in some other cancers, such as gastric cancer.<sup>65–68</sup> It is valuable to examine the expression of the miRs in clinical tissues. TCGA is a common database; however, there are no data about Survivin-OSA in TCGA. Therefore, we examined the expression level of miR-596 and Survivin in clinical specimens.

Furthermore, subcutaneous tumors are a common research model for the antitumor effects of drugs. This study established a subcutaneous tumor research model to examine the role of anlotinib. However, it is difficult to inspect the invasion and destruction of OSA cells on muscle and other tissues through simple subcutaneous tumors. For this reason, OSA cells were directly injected into the muscle tissue of nude mice for PET imaging in small animals. The growth of OSA cells in the muscle tissues was examined by the pathological analysis of tissues. The quantitative analysis of the images of pathological analysis finally determined the damage of OSA cells in muscle tissues.

## Conclusion

miR-596 targets Survivin and enhances the antitumor effect of anlotinib on OSA cells.

## Abbreviations

OSA, osteosarcoma; miR, microRNAs; VEGFR2, vascular endothelial growth factor receptor 2; platelet-derived

growth factor receptors  $\alpha/\beta$ , PDGFR  $\alpha/\beta$ ; discoidin domain receptor 1, DDR1; non-small-cell lung cancer (NSCLC); HCC, hepatocarcinoma; OS, survival; PFS, progression-free survival; RTK, receptor tyrosine protein kinase; MAPK, mitogen-activated protein kinase; BIRC5, baculoviral inhibitor of apoptosis repeat-containing.

## Acknowledgment

We thank Prof. Xiaojie Xu in Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Palo Alto, Beijing, China, and Dr. Fan Feng in Research Center for Clinical and Translational Medicine, the Fifth Medical Center of the General Hospital of the Chinese People's Liberation Army, Beijing, China, for their help and advice.

## Author contributions

All authors made substantial contributions to the design and conception, acquisition, analysis, or interpretation of data. All authors took part in either drafting or revising the manuscript. All authors also gave final approval of the version to be published and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

## Disclosure

The authors report no conflicts of interest in this work.


## References

- Edelmann MN, Daryani VM, Bishop MW, et al. Neurocognitive and patient-reported outcomes in adult survivors of childhood osteosarcoma. *JAMA Oncol.* 2016;2:201–208. doi:10.1001/jamaoncol.2015.4398
- Whelan JS, Davis LE. Osteosarcoma, chondrosarcoma, and chordoma. *J Clin Oncol.* 2018;36:188–193. doi:10.1200/JCO.2017.75.1743. Epub 2017 Dec 8.

3. Ji Q, Xu X, Li L, et al. miR-216a inhibits osteosarcoma cell proliferation, invasion and metastasis by targeting CDK14. *Cell Death Dis.* 2017;8:e3103. doi:10.1038/cddis.2017.499
4. Lagmay JP, Krailo MD, Dang H, et al. Outcome of patients with recurrent osteosarcoma enrolled in seven Phase II trials through children's cancer group, pediatric oncology group, and children's oncology group: learning from the past to move forward. *J Clin Oncol.* 2016;34:3031–3038. doi:10.1200/JCO.2015.65.5381
5. Wang G, Sun M, Jiang Y, et al. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma. *Int J Cancer.* 2019;145:979–993. doi:10.1002/ijc.32180
6. Si X, Zhang L, Wang H, et al. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: experiences in ALTER-0303. *Thorac Cancer.* 2019;10:551–556. doi:10.1111/1759-7714.12977
7. Chen HM, Feng G. Use of anlotinib in intra-abdominal desmoplastic small round cell tumors: a case report and literature review. *Oncotargets Ther.* 2018;12:57–61. doi:10.2147/OTT.S190333
8. Chen XZ. Anlotinib for refractory advanced non-small cell lung cancer in China. *JAMA Oncol.* 2019;5:116–117. doi:10.1001/jamaoncol.2018.5526
9. Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. *J Hematol Oncol.* 2018;11:120. doi:10.1186/s13045-018-0664-7
10. Liu W, Jiang Q, Zhou Y. Advances of systemic treatment for adult soft-tissue sarcoma. *Chin Clin Oncol.* 2018;7:42. doi:10.21037/cco.2018.08.02
11. Wirries A, Jabari S, Jansen EP, et al. Panobinostat mediated cell death: a novel therapeutic approach for osteosarcoma. *Oncotarget.* 2018;9:32997–33010. doi:10.18632/oncotarget.26038
12. Soleimanpour E, Babaei E. Survivin as a potential target for cancer therapy. *Asian Pac J Cancer Prev.* 2015;16:6187–6191. doi:10.7314/apjcp.2015.16.15.6187
13. Bashash D, Safaroghli-Azar A, Dadashi M, Safa M, Momeny M, Ghaffari SH. Anti-tumor activity of PI3K- $\delta$  inhibitor in hematologic malignant cells: shedding new light on resistance to idelalisib. *Int J Biochem Cell Biol.* 2017;85:149–158. doi:10.1016/j.biocel.2017.02.007
14. Lyu H, Wang S, Huang J, Wang B, He Z, Liu B. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer. *Cancer Lett.* 2018;420:97–108. doi:10.1016/j.canlet.2018.01.065
15. Liang Y, Xu X, Wang T, et al. The EGFR/miR-338-3p/EYA2 axis controls breast tumor growth and lung metastasis. *Cell Death Dis.* 2017;8:e2928. doi:10.1038/cddis.2017.325
16. Li L, Kang L, Zhao W, et al. miR-30a-5p suppresses breast tumor growth and metastasis through inhibition of LDHA-mediated Warburg effect. *Cancer Lett.* 2017;400:89–98. doi:10.1016/j.canlet.2017.04.034
17. Li J, Zhao J, Wang H, et al. MicroRNA-140-3p enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting pregnenolone X receptor. *Oncotargets Ther.* 2018;11:5885–5894. doi:10.2147/OTT.S179509
18. Khan NM, Haqqi TM. Epigenetics in osteoarthritis: potential of HDAC inhibitors as therapeutics. *Pharmacol Res.* 2018;128:73–79. doi:10.1016/j.phrs.2017.08.007
19. Fan Z, Duan J, Wang L, et al. PTK2 promotes cancer stem cell traits in hepatocellular carcinoma by activating Wnt/ $\beta$ -catenin signaling. *Cancer Lett.* 2019;450:132–143. doi:10.1016/j.canlet.2019.02.040
20. Cao Y, Trillo-Tinoco J, Sierra RA, et al. ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression. *Nat Commun.* 2019;10:1280. doi:10.1038/s41467-019-09263-1
21. Wang L, Zhao L, Jia X, et al. Aminophenols increase proliferation of thyroid tumor cells by inducing the transcription factor activity of estrogen receptor  $\alpha$ . *Biomed Pharmacother.* 2019;109:621–628. doi:10.1016/j.biopha.2018.10.168
22. Ma H, Yao Y, Wang C, et al. Transcription factor activity of estrogen receptor  $\alpha$  activation upon nonylphenol or bisphenol A treatment enhances the in vitro proliferation, invasion, and migration of neuroblastoma cells. *Oncotargets Ther.* 2016;9:3451–3463. doi:10.2147/OTT.S105745
23. Feng F, Jiang Q, Cao S, et al. Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma. *Biochim Biophys Acta Gen Subj.* 2018;1862:1017–1030. doi:10.1016/j.bbagen.2018.01.011
24. Guan F, Ding R, Zhang Q, et al. WX-132-18B, a novel microtubule inhibitor, exhibits promising anti-tumor effects. *Oncotarget.* 2017;8:71782–71796. doi:10.18632/oncotarget.17710
25. Li F, Wei A, Bu L, et al. Pro-caspase-3-activating compound 1 stabilizes hypoxia-inducible factor 1 $\alpha$  and induces DNA damage by sequestering ferrous iron. *Cell Death Dis.* 2018;9:1025. doi:10.1038/s41419-018-1038-3
26. Wang Y, Tang Z. A novel long-sustaining system of apatinib for long-term inhibition of the proliferation of hepatocellular carcinoma cells. *Oncotargets Ther.* 2018;11:8529–8541. doi:10.2147/OTT.S188209. eCollection 2018.
27. Wu M, Zhao G, Zhuang X, et al. Triclosan treatment decreased the antitumor effect of sorafenib on hepatocellular carcinoma cells. *Oncotargets Ther.* 2018;11:2945–2954. doi:10.2147/OTT.S165436
28. Zhang Y, Li D, Jiang Q, et al. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. *Cell Death Dis.* 2018;9:743. doi:10.1038/s41419-018-0804-6
29. Li L, Liang Y, Kang L, et al. Transcriptional regulation of the warburg effect in cancer by SIX1. *Cancer Cell.* 2018;33:368–385. e7. doi:10.1016/j.ccell.2018.01.010
30. Xu X, Fan Z, Kang L, et al. Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. *J Clin Invest.* 2013;123:630–645. doi:10.1172/JCI64265
31. Shao Z, Li Y, Dai W, et al. ETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR. *Pharmacol Res.* 2018;135:188–200. doi:10.1016/j.phrs.2018.08.003
32. Meng D, Meng M, Luo A, et al. Effects of VEGFR1 + hematopoietic progenitor cells on pre-metastatic niche formation and in vivo metastasis of breast cancer cells. *J Cancer Res Clin Oncol.* 2019;145:411–427. doi:10.1007/s00432-018-2802-6
33. Meng D, Lei M, Han Y, et al. MicroRNA-645 targets urokinase plasminogen activator and decreases the invasive growth of MDA-MB-231 triple-negative breast cancer cells. *Oncotargets Ther.* 2018;11:7733–7743. doi:10.2147/OTT.S187221
34. Wei L, Lun Y, Zhou X, et al. Novel urokinase-plasminogen activator inhibitor SPINK13 inhibits growth and metastasis of hepatocellular carcinoma in vivo. *Pharmacol Res.* 2019;143:73–85. doi:10.1016/j.phrs.2019.03.009
35. Lacial PM, Graziani G. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors. *Pharmacol Res.* 2018;136:97–107. doi:10.1016/j.phrs.2018.08.023
36. Rajagopal C, Lankadasari MB, Aranjani JM, Harikumar KB. Targeting oncogenic transcription factors by polyphenols: a novel approach for cancer therapy. *Pharmacol Res.* 2018;130:273–291. doi:10.1016/j.phrs.2017.12.034
37. Jr RR, Sadeghi-Nejad A. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers. *Pharmacol Res.* 2018;128:1–17. doi:10.1016/j.phrs.2017.12.021

38. Tewari D, Nabavi SF, Nabavi SM, et al. Targeting activator protein 1 signaling pathway by bioactive natural agents: possible therapeutic strategy for cancer prevention and intervention. *Pharmacol Res.* 2018;128:366–375. doi:10.1016/j.phrs.2017.09.014
39. Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors. *Pharmacol Res.* 2019;144:19–50. doi:10.1016/j.phrs.2019.03.006
40. Roskoski R Jr. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. *Pharmacol Res.* 2018;135:239–258. doi:10.1016/j.phrs.2018.08.013
41. Roskoski R Jr. The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders. *Pharmacol Res.* 2018;129:65–83. doi:10.1016/j.phrs.2018.01.021
42. Zhu YJ, Zheng B, Wang HY, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. *Acta Pharmacol Sin.* 2017;38:614–622. doi:10.1038/aps.2017.5
43. Feng F, Jiang Q, Jia H, et al. Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis. *Pharmacol Res.* 2018;135:89–101. doi:10.1016/j.phrs.2018.06.021
44. Frassanito MA, Saltarella I, Vinella A, et al. Survivin overexpression in head and neck squamous cell carcinomas as a new therapeutic target (Review). *Oncol Rep.* 2019;41:2615–2624. doi:10.3892/or.2019.7082
45. Dinesh P, Rasool M. uPA/uPAR signaling in rheumatoid arthritis: Shedding light on its mechanism of action. *Pharmacol Res.* 2018;134:31–39. doi:10.1016/j.phrs.2018.05.016
46. Shojaei F, Yazdani-Nafchi F, Banitalebi-Dehkordi M, Chehelgerdi M, Khorramian-Ghahfarokhi M. Trace of survivin in cancer. *Eur J Cancer Prev.* 2019;28:365–372. doi:10.1097/CEJ.0000000000000453
47. Li D, Hu C, Li H. Survivin as a novel target protein for reducing the proliferation of cancer cells. *Biomed Rep.* 2018;8:399–406. doi:10.3892/br.2018.1077
48. Khan Z, Khan AA, Yadav H, Prasad GBKS, Bisen PS. Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma. *Cell Mol Biol Lett.* 2017;22:8. doi:10.1186/s11658-017-0038-0
49. Jia H, Yang Q, Wang T, et al. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents. *Biochim Biophys Acta.* 2016;1860:1417–1430. doi:10.1016/j.bbagen.2016.04.007
50. Kang J, Kim E, Kim W, et al. Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines. *J Biol Chem.* 2013;288:27343–27357. doi:10.1074/jbc.M113.490482
51. Braný D, Dvorská D, Slávik P, Školka R, Adamkov M. Survivin and gynaecological tumours. *Pathol Res Pract.* 2017;213:295–300. doi:10.1016/j.prp.2017.02.009
52. Xie Y, Ma X, Gu L, et al. Prognostic and clinicopathological significance of survivin expression in renal cell carcinoma: a systematic review and meta-analysis. *Sci Rep.* 2016;6:29794. doi:10.1038/srep29794
53. De Vita A, Recine F, Mercatali L, et al. Primary culture of undifferentiated pleomorphic sarcoma: molecular characterization and response to anticancer agents. *Int J Mol Sci.* 2017;18pii:E2662. doi:10.3390/ijms18122662
54. Yang X, Xia W, Chen L, et al. Synergistic antitumor effect of a  $\gamma$ -secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma. *Oncotarget.* 2018;9:34996–35007. doi:10.18632/oncotarget.26209
55. An L, Li DD, Chu HX, et al. Terfenadine combined with epirubicin impedes the chemo-resistant human non-small cell lung cancer both in vitro and in vivo through EMT and Notch reversal. *Pharmacol Res.* 2017;124:105–115. doi:10.1016/j.phrs.2017.07.021
56. Zhang Y, Li D, Feng F, et al. Progressive and prognosis value of notch receptors and ligands in hepatocellular carcinoma: a systematic review and meta-analysis. *Sci Rep.* 2017;7:14809. doi:10.1038/s41598-017-14897-6
57. Li DD, Zhao CH, Ding HW, et al. A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-Fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo. *Cell Prolif.* 2018;51:e12480. doi:10.1111/cpr.12480
58. Liu L, Tian YC, Mao G, Zhang YG, Han L. MiR-675 is frequently overexpressed in gastric cancer and enhances cell proliferation and invasion via targeting a potent anti-tumor gene PITX1. *Cell Signal.* 2019;62:109352. doi:10.1016/j.cellsig.2019.109352
59. Kochan-Jamroz K, Króliczewski J, Moszyńska A, Collawn JF, Bartoszewski R. miRNA networks modulate human endothelial cell adaptation to cyclic hypoxia. *Cell Signal.* 2019;54:150–160. doi:10.1016/j.cellsig.2018.11.020
60. Xiong H, Yan T, Zhang W, et al. miR-613 inhibits cell migration and invasion by downregulating Daam1 in triple-negative breast cancer. *Cell Signal.* 2018;44:33–42. doi:10.1016/j.cellsig.2018.01.013
61. Momen-Heravi F, Bala S. Emerging role of non-coding RNA in oral cancer. *Cell Signal.* 2018;42:134–143. doi:10.1016/j.cellsig.2017.10.009
62. Luo M, Wu L, Zhang K, et al. miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma. *Cell Signal.* 2018;42:30–43. doi:10.1016/j.cellsig.2017.09.024
63. Sanchez V, Golyardi F, Mayaki D, et al. Negative regulation of angiogenesis by novel micro RNAs. *Pharmacol Res.* 2019;139:173–181. doi:10.1016/j.phrs.2018.11.010
64. Hasanpourghadi M, Pandurangan AK, Mustafa MR. Modulation of oncogenic transcription factors by bioactive natural products in breast cancer. *Pharmacol Res.* 2018;128:376–388. doi:10.1016/j.phrs.2017.09.009
65. Wang H, Liu L, Fang S. MicroRNA-330-5p inhibits osteosarcoma cell growth and invasion by targeting the proto-oncogene survivin. *Mol Med Rep.* 2019. doi:10.3892/mmr.2019.10447
66. Tong X, Yang P, Wang K, et al. Survivin is a prognostic indicator in glioblastoma and may be a target of microRNA-218. *Oncol Lett.* 2019;18:359–367. doi:10.3892/ol.2019.10335
67. Vahidi Manesh P, Farazmand A, Gharibdoost F, et al. Downregulation of miR-542-3p contributes to apoptosis resistance in dermal fibroblasts from systemic sclerosis patients via survivin overexpression. *Iran J Allergy Asthma Immunol.* 2019;18:173–181.
68. Xu S, Li D, Li T, et al. miR-494 sensitizes gastric cancer cells to TRAIL treatment through downregulation of survivin. *Cell Physiol Biochem.* 2018;51:2212–2223. doi:10.1159/000495867

## Supplementary materials



**Figure S1** miR-596 inhibited the activation of luciferase reporters containing 3'UTR sequence of Survivin. The wild-type sequence or sequence with mutated miR-596-binding site of Survivin's 3'UTR (1921–2100) was obtained by chemical synthesis and cloned into pGL4.26 plasmids to construct luciferase reporters by Vigene Corporation, Jinan City, Shandong Province, China. The luciferase containing wild-type sequence of Survivin's 3'UTR with miR-596-binding site was named as Luc, whereas the luciferase containing a sequence of Survivin's 3'UTR with mutated miR-596-binding site was named as Luc<sup>Mut</sup>. Cells were transfected with control miRNA + Luc, miR-596 + Luc, miR-596 + inhibitor + Luc or miR-596 + Luc<sup>Mut</sup>. Then, cells were harvested for luciferase experiments. Results were shown as mean  $\pm$  SD of relative luciferase activation. \* $P < 0.05$ .

**Table S1** The baseline characters of patients included

Characteristics	n (%)
Total number	74
Gender	
Male	41 (55.4)
Female	33 (44.6)
Tumor size (cm)	
> 7	49 (60.8)
$\leq$ 7	25 (39.2)
TNM stage	
I	32 (43.2)
II	25 (33.7)
III	17 (51.6)
Location	
Distal femur	31 (41.9)
Proximal femur	7 (9.4)
Proximal humerus	13 (17.5)
Proximal tibia	20 (27.0)
Others	3 (4.0)
Relapse	
Yes	11 (14.9)
No	63 (85.1)
Metastasis location	
Lung	21 (28.3)
Others	4 (5.4)
None	49 (66.2)

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>